NMDA-SDS-MedChemExpress

Inhibitors, Agonists, Screening Data SheetBIOLOGICAL ACTIVITY: NMDA is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at thatreceptor.In Vitro: NMDA exerts a significant augmentation of the adrenal binding independently of the incubation temperature in aconcentration–dependent manner[2]. In Vivo: NMDA (0.2 nM) shows significant effects on MF, IF, IL, and EL, respectively, decreasing the mount and intromissionfrequencies, and shortening the intromission and ejaculation latencies. NMDA and AP–5 significantly, respectively, facilitates andinhibits the ejaculatory behavior during the copulation testing 30 min. Bilateral microinjection of NMDA into PVN significantlyincreases the baseline LSNA, the peaking increment of LSNA occurred within 5 min from the time of NMDA microinjected into PVN[1]. PROTOCOL (Extracted from published papers and Only for reference) Kinase Assay:[2]Adrenal membranous homogenate suspensions are incubated with 10 nM [3H]Glu in 500/zl 50 mM Tris–acetatebuffer (pH 7.4) at 2°C or 30°C in the presence and absence of various compounds. Incubation is terminated by the addition of 3mL ice–cold buffer and subsequent filtration through a Whatman GF/B glass filter under a constant vacuum of 15 mm Hg. Afterwashing the filter 4 times with 3 mL icecold buffer, the radioactivity trapped on the filter is measured by a liquid scintillationspectrometer using 5 mL modified Triton–toluene scintillant at a counting efficiency of 40–42%. The radioactivity found in thepresence of 1 mM non–radioactive Glu is subtracted from each experimental value to obtain the specific binding of [3H]GIu inaccordance with the y–aminobutyric acid (GABA) receptor binding assay system. The kinetic parameters of [3H]GIu binding, Kd andBma x, are calculated by Scatchard analysis of the specific binding using a personal computer with a programme for non–linearregression analysis developed in our own laboratory.Animal Administration: NMDA is formulated in saline.[1]Thirty male rats are paired with different receptive females for a total of threetimes (once every 3 days) a week prior to the experiment, only the males that ejaculated at least three times during this period areincluded. After selecting the male rats with normal ejaculatory ability. Saline (100 nL), NMDA (0.20 nmol in 100 nL saline), and AP–5(10.0 nmol in 100 nL saline) are adminitration into the bilateral PVN of each male rat in random order. After 5 min, the behavioraltesting is performed and recorded as described above. Copulatory behaviors occur once a week and the entire experiment lasted 4weeks.References: [1]. Xia JD, et al. Centrally mediated ejaculatory response via sympathetic outflow in rats: role of N–methyl–D–aspartic acid receptors in paraventricularnucleus. Andrology. 2016 Nov 16.[2]. Yoneda Y, et al. Enhancement of [3H]glutamate binding by N–methyl–D–aspartic acid in rat adrenal. Brain Res. 1987 Mar 17;406(1–2):24–31.Product Name:NMDACat. No.:HY-17551CAS No.:6384-92-5Molecular Formula:C5H9NO4Molecular Weight:147.13Target:iGluR; iGluRPathway:Membrane Transporter/Ion Channel; Neuronal SignalingSolubility:DMSO: ≥15 mg/mL (Need ultrasonic and warming to 60¡æ)

Inhibitors, Agonists, Screening Certificate of Analysis

PHYSICAL AND CHEMICAL PROPERTIES Molecular Formula:C9H10O4Molecular Weight:182.17Storage:4°C, stored under nitrogenChemical Structure:ANALYTICAL DATA Appearance:White to off-white (Solid)1 H NMR Spectrum:Consistent with structureGC:Consistent with structurePurity (GC):99.96%Conclusion:The product has been tested and complies with the given specifications.Product Name:SyringaldehydeCat. No.:HY-N1390CAS No.:134-96-3Batch No.:29222Chemical Name:Benzaldehyde, 4-hydroxy-3,5-dimethoxy-

Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852,

Inhibitors, Agonists, Screening Safety Data SheetRevision Date:Oct.-03-2018Print Date:Oct.-03-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :NMDACatalog No. :HY-17551CAS No. :6384-92-51.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsPage 1 of None.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:N-Methyl-D-aspartic acidFormula:C5H9NO4Molecular Weight:147.13CAS No. :6384-92-54. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers toensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouthresuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safeareas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment byscrubbing with alcohol; Dispose of contaminated material according to Section 13.Page 2 of 7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C3 years4°C2 yearsIn solvent-80°C6 months-20°C1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protectionSafety goggles with side-shields.Hand protectionProtective gloves.Skin and body protectionImpervious clothing.Respiratory protectionSuitable respirator.Environmental exposure controlsKeep the product away from drains, water courses or the soil. Clean spillages in asafe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearanceWhite to off-white (Solid)OdorNo data availableOdor thresholdNo data availablepHNo data availableMelting/freezing pointNo data availableBoiling point/rangeNo data availableFlash pointNo data availableEvaporation rateNo data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limitsNo data availableVapor pressureNo data availableVapor densityNo data availableRelative densityNo data availablePage 3 of

MSDS

1 Composition7 Accident Release Measure

Product Name:Ruxolitinib phosphate

Chemical Name:PROCEDURE(S) OF PERSONAL PRECAUTION(S)-Wear

respirator, chemical safety goggles, rubber boots, and heavy

rubber gloves.

METHODS FOR CLEANING UP-Sweep up, place in a bag and

hold for waste disposal. Avoid raising dust. Ventilate area and

wash spill site after material pickup is complete.1H-Pyrazole-1-propanenitrile, .beta.-cyclopentyl-4-(7H-

pyrrolo[2,3-d]pyrimidin-4-yl)-, (.beta.R)-, phosphate (1:1)

CAS No.:1092939-17-78 Accident Release Measure

Appearance: White to gray(Solid)

Formula:C17H21N6O4P9 Toxicological Information

Solubility:To the best of our knowledge, the chemical, physical, and

toxicological properties have not been thoroughly investigated.No data available.pppp

DMSO

2 Handling and Storage10 Regulary Information